Exact Sciences delivered solid Q1 2025 performance with 11% revenue growth, improved profitability metrics, and the launch of two key diagnostic products, despite continuing to report a net loss.
Revenue rose to $707 million, up 11% from the previous year.
Net loss narrowed to $101 million, or $0.54 per share.
Cologuard Plus and Oncodetect were successfully launched.
Adjusted EBITDA jumped 61% to $63 million.
Exact Sciences raised its full-year 2025 revenue and adjusted EBITDA guidance based on Q1 momentum and product rollouts.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance